Retatrutide vs Semaglutide: What's the Difference?

Retatrutide and semaglutide are both injectable, once-weekly incretin medicines, but they represent two different generations and two different stages of development. Semaglutide is an established, FDA-approved GLP-1 medicine sold as Ozempic, Wegovy, and (in oral form) Rybelsus. Retatrutide is a newer, investigational triple agonist that is not approved. Here's an honest comparison of what is publicly known.

Important: Retatrutide is not FDA-approved and cannot be prescribed as an approved medicine. The information below is educational, drawn from published trials, and is not medical advice.

What is the difference between retatrutide and semaglutide?

Semaglutide is a single-receptor agonist: it activates only the GLP-1 receptor. Retatrutide is a triple agonist that activates three receptors (GLP-1, GIP, and glucagon) with one molecule. The added GIP and glucagon activity is what distinguishes retatrutide from single- and dual-agonist drugs, and researchers believe the glucagon component may increase energy expenditure.

Side-by-side comparison

Retatrutide: the investigational triple agonist

Retatrutide is a synthetic 39-amino-acid peptide from Eli Lilly. In its Phase 2 obesity trial (New England Journal of Medicine), the 12 mg weekly dose produced a mean weight reduction of about 24.2% at 48 weeks. It has a roughly 6-day half-life supporting once-weekly injection, and it is now in the Phase 3 TRIUMPH program, with topline data reported through 2026. Despite the striking early numbers, retatrutide remains investigational. It is not available by prescription, and only ongoing trials and any future regulatory review will establish its true safety and efficacy.

Semaglutide: the established GLP-1 medicine

Semaglutide is one of the most widely used incretin medicines. It is marketed as Ozempic (type 2 diabetes), Wegovy (chronic weight management), and Rybelsus (an oral tablet for diabetes). The injectable versions are given once weekly, with providers escalating the dose gradually. Wegovy, for example, is titrated toward a 2.4 mg weekly maintenance dose under medical supervision. In obesity trials semaglutide produced meaningful weight loss (around 15%), and it has extensive approved labeling and cardiovascular outcome data behind it.

Which is more effective for weight loss?

In separate trials, retatrutide's Phase 2 weight-loss figures were numerically higher than semaglutide's obesity-trial figures. But these are not head-to-head results, the trial designs and populations differ, and retatrutide is not finished with Phase 3. A larger number in an early trial does not make an investigational drug "better" than an approved one. Approval requires the full body of safety and efficacy evidence that semaglutide already has and retatrutide does not yet.

Are the side effects different?

Both are incretin-based and share a broadly similar side-effect pattern dominated by gastrointestinal events (nausea, vomiting, diarrhea, constipation), mostly during dose escalation. Semaglutide tends toward nausea and constipation. Retatrutide's Phase 2 data noted GI events plus a dose-dependent, transient rise in heart rate. Retatrutide's complete safety profile is still being characterized.

Can I get retatrutide instead of semaglutide?

No. Retatrutide is investigational and cannot be prescribed as an approved medicine, whereas semaglutide is approved and available through a healthcare provider. Any product marketed as "retatrutide" outside a clinical trial is not an FDA-approved medicine. Discuss approved options with your provider.

Medical Disclaimer

This page is general educational information, not medical advice. Retatrutide is investigational and not FDA-approved. Trial figures are reported as published in the referenced studies and are not dosing recommendations. RetaPal is a private tracking and reminder app only. It does not recommend, calculate, or suggest doses. Always follow the dose and schedule given by your own prescriber, and consult your healthcare provider before starting, stopping, or changing any medication.

Once you and your provider have set a plan, RetaPal can log your weekly dose and count down to your next injection, privately, offline, and without ever suggesting a dose.